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Abstract  
AIM: To assess the efficacy and safety of ipragliflozin as add-on therapy to metformin in 
Russian patients with type 2 diabetes mellitus. 
METHODS: In this double-blind study conducted in 14 centers in Russia, 165 patients were 
randomized 2:1 to ipragliflozin (50 mg/day) or placebo for 24 weeks while continuing 
metformin. Patients who had HbA1c ≥7.0% (53 mmol/mol) at Week 12 received open-label 
ipragliflozin (50 mg/day) in addition to the blinded drug from Week 12–24. 
RESULTS: Significant reductions in HbA1c and body weight from baseline to Week 12 in 
favor of ipragliflozin were observed (adjusted mean difference to placebo: -0.3% (-3 
mmol/mol) , P=0.048 and -1.34 kg, P<0.001, respectively). The incidence of AEs was similar 
in both groups. Uptitration to 100 mg/day ipragliflozin led to a further reduction in body 
weight (mean change from Week 12: -0.65 kg, P=0.004) and an additional 13% (9/69) of 
patients achieving HbA1c <7.0% (53 mmol/mol) at Week 24. Incidence of AEs was similar 
among patients receiving ipragliflozin 50 mg/day (23.7%) and 100 mg/day (24.6%).  
CONCLUSION: Ipragliflozin 50 mg/day added to metformin significantly reduced HbA1c and 
body weight after 12 weeks and showed a safety profile comparable to placebo. Uptitration 
to 100 mg/day improved clinical outcomes with no additional safety concerns. 
 
KEYWORDS: Diabetes mellitus, type 2; Ipragliflozin; Metformin; Randomized controlled trial; 
Sodium-glucose co-transporter-2 (SGLT2) inhibitor  
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1. Introduction 
Type 2 diabetes mellitus (T2DM) is a growing concern worldwide, having reached epidemic 
proportions in many developing and most developed countries [1]. Data from the Russian 
State Diabetes Registry estimated the prevalence of T2DM in Russia at 2.97%; however, the 
2016 NATION study suggests it is much higher at 5.4%, where over half were undiagnosed 
[2]. Despite efforts to estimate the prevalence of diabetes in Russia [1, 2], the true 
prevalence of T2DM is likely to be even higher than reported. 
Current international treatment guidelines recommend the use of metformin as first-line 
therapy in patients with T2DM, in conjunction with lifestyle interventions such as diet and 
exercise [3, 4]. If glucose control remains inadequate, a combination of metformin and one 
of the following class of antidiabetic agents is recommended: sulfonylureas, dipeptidyl 
peptidase 4 inhibitors, thiazolidinediones, GLP-1 receptor agonists, or sodium-glucose co-
transporter-2 (SGLT2) inhibitors [3, 4]. Among these, SGLT2 inhibitors are the only class of 
oral antidiabetic agents that improve glycemic control by an insulin-independent 
mechanism. SGLT2 inhibitors lower blood glucose by reducing glucose reabsorption and 
increasing urinary excretion of glucose [5]. Given that SGLT2 inhibitors work independently 
of insulin secretion and action, progressive β-cell failure in T2DM does not attenuate their 
efficacy and they may therefore be used at any stage of T2DM, including in combination 
with insulin therapy. 
Ipragliflozin is a SGLT2 inhibitor that has been approved for use in the treatment of T2DM in 
Japan and Korea [6, 7]. Its beneficial effects on glycemic control and body weight have been 
demonstrated in a number of randomized, double-blind, placebo-controlled trials [8-16]. 
Since then, a post-marketing long-term study of ipragliflozin has further demonstrated its 
efficacy and safety in patients with T2DM [17]. While the efficacy and safety of ipragliflozin 
have been demonstrated in previous phase 3 trials, the majority of these trials were 
conducted in Asia. Thus, this phase 3, double-blind, randomized, placebo-controlled study 
aimed to examine the efficacy and safety of ipragliflozin as an add-on therapy to metformin 
in Russian patients with inadequately controlled T2DM.   
  
4 
 
2. Materials and methods 
This phase 3, double-blind, randomized study was conducted between May 2016 and June 
2017 at 14 sites in Russia. The local independent ethics committee at each site reviewed and 
approved the study protocol and documents used for informed consent prior to study 
initiation. The study was conducted in accordance with Good Clinical Practice, the 
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use guidelines, and the Declaration of Helsinki [18]. All patients provided written 
informed consent before any study-related procedures were performed. This study was 
registered at ClinicalTrials.gov (identifier NCT02794792). 
2.1 Study population 
Patients were assessed for study eligibility at the screening visit. Key inclusion criteria 
included: aged ≥18 years; diagnosed with T2DM for ≥12 weeks; treated with metformin at a 
stable dose of ≥1500 mg/day for ≥12 weeks; glycated hemoglobin (HbA1c) between 7.5% 
(58 mmol/mol) and 11.0% (97 mmol/mol) (inclusive); and body mass index (BMI) between 
20 to 45 kg/m2 (inclusive). Key exclusion criteria were: type 1 diabetes mellitus; treated with 
any medication for glycemic control (except metformin) within 12 weeks; received systemic 
corticosteroids within 12 weeks; had a stroke, unstable angina, myocardial infarction, any 
vascular intervention or heart failure within 12 weeks; history of diabetic coma or precoma; 
history of ketoacidosis or lactic acidosis; and pregnant or lactating. A full list of inclusion and 
exclusion criteria is available in the supplementary material. 
2.2 Study design and treatments  
Patients were enrolled by study investigators. Eligible patients entered a 2-week placebo 
run-in period, during which single-blind placebo was given in addition to metformin; 
patients’ ability to adhere to the treatment regimen and protocol procedures was assessed. 
This was followed by a 24-week double-blind treatment period (consisting of Period I [Week 
0–12] and Period II [Week 12–24]) where patients were randomized (2:1) to ipragliflozin (50 
mg/day) or placebo while continuing metformin treatment. A centralized designated 
interactive web response system (Cenduit, Allschwil, Switzerland) was used to randomize 
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and assign patients to ipragliflozin or placebo treatment. The randomization was stratified 
by study center using a block design procedure. At the end of Period I, patients with HbA1c 
≥7.0% (53 mmol/mol) and who did not have intolerable adverse events potentially related 
to ipragliflozin were uptitrated by addition of open-label ipragliflozin (50 mg/day) to their 
blinded treatment for a further 12 weeks (Period II); patients with HbA1c <7.0% (53 
mmol/mol) at the end of Period I continued their double-blind treatment regimen without 
uptitration in Period II. Only patients that completed the 12-week treatment period in 
Period I were included in Period II. All patients were followed for a further 4 weeks after the 
end of treatment.  
Metformin tablets were provided by the sponsor from the placebo run-in period until the 
end of study. Glucometers and test strips used were standardized across study sites and 
provided to patients for monitoring of blood glucose twice daily (fasting and 2 hours after a 
meal) on at least 2 days each week until the end of the study. Glucometer readings were 
recorded in patient diaries and reviewed by the investigator at each visit. The study 
medications (i.e. placebo and ipragliflozin) were indistinguishable in terms of appearance, 
taste and aroma. Assignment to study medications was blinded to patients, investigators, 
clinical staff, and the study sponsor. To maintain blinding, measurements of urinary glucose 
were not made available to the investigators during the study period. With the exception of 
the prescribed study medications and metformin, use of any drugs that affect plasma 
glucose levels was prohibited during the study period. Systemic corticosteroids and changes 
to diet and exercise were also prohibited until the end of the study. 
2.3 Study endpoints 
The primary efficacy endpoint was the change in HbA1c from baseline (Week 0) to the end 
of Period I. Secondary endpoints included the change in fasting plasma glucose (FPG), body 
weight, and waist circumference during Period I and II, and the change in HbA1c during 
Period II. Key safety endpoints included the incidence of treatment-emergent adverse 
events (TEAEs), TEAEs leading to treatment discontinuation, as well as changes in vital signs 
(systolic blood pressure, diastolic blood pressure, and pulse rate), clinical laboratory 
variables (lipid profile, hematology, biochemistry, and urinalysis), and 12-lead 
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electrocardiogram (ECG). All clinical laboratory assessments were conducted in a central 
laboratory (BARC Global Central Laboratory, Gent, Belgium).  
TEAEs were defined as adverse events that were observed after the first administration of 
study medication to the end of the study. TEAEs of special interest included hypoglycemia, 
urinary tract infection, and genital infection. Classification of hypoglycemic events follow the 
definitions from the American Diabetes Association and Endocrine Society workgroup report 
[19].  
2.4 Statistical analyses 
It was estimated that a sample size of 156 evaluable patients would provide approximately 
90% power to detect a statistically significant difference between placebo and ipragliflozin 
in HbA1c change from baseline at the end of the first 12-week treatment period, assuming a 
real treatment mean effect of at least 0.5% (6 mmol/mol) change in HbA1c from baseline, a 
common standard deviation (SD) of 0.9% (10 mmol/mol), and a 2 sided significance level of 
α = 0.05. Assuming that approximately 5% of randomized patients may discontinue prior to 
the week 12 visit, a total of 165 randomized patients would be required for the study.  
Sample size assumptions were based on the results of two earlier phase 3 studies of 
ipragliflozin [8, 10]. 
There were two treatment groups in Period I based on the randomized study medication 
received: placebo and ipragliflozin. There were four treatment groups in Period II based on 
the randomized study medication received in Period I and the titration decision made at the 
start of Period II: placebo/placebo (randomized to placebo, not uptitrated), 
placebo/ipragliflozin 50 mg (randomized to placebo, uptitrated), ipragliflozin/ipragliflozin 50 
mg (randomized to ipragliflozin, not uptitrated), ipragliflozin/ipragliflozin 100 mg 
(randomized to ipragliflozin, uptitrated).  
The full analysis set (FAS) consisted of all patients who were randomized and received at 
least one dose of the study medication during Period I and had at least one post-baseline 
efficacy measurement. The safety analysis set (SAF) consisted of all patients who took at 
least one dose of the randomized study medication during the treatment period.  
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Primary and secondary efficacy outcomes were assessed in the FAS and safety outcomes 
were assessed in the SAF. Missing values at the end of each treatment period were derived 
using the last observation carried forward method. Study medication compliance was 
calculated as (number of tablets of study medication taken x 100)/number of tablets that 
should have been taken since the previous visit. Demographics, baseline characteristics, and 
safety assessments were summarized by treatment group using descriptive statistics. 
Continuous variables were reported as means and SD, while categorical data were 
expressed as n (%) in each treatment group. Changes in primary and secondary efficacy 
endpoints during Period I (from baseline to Week 12) were compared between treatment 
groups using analysis of covariance (ANCOVA) with treatment as a fixed effect, center as a 
random effect, and the respective baseline value as a covariate. For data collected during 
Period II, mean and 95% confidence intervals (CI) were calculated for change from week 12 
(end of Period I/start of Period II) to end of Period II (Week 24) using the analysis of variance 
(ANOVA) model with treatment group as a fixed effect.  
After the planned analyses were completed, a >1% (11 mmol/mol) change in HbA1c was 
noted during the placebo run-in period in 17 patients (10.4%) in the FAS, suggesting that 
these patients may not have reached a stable HbA1c by baseline as planned for in the design 
of the study. To assess the impact that the patients with unstable HbA1c at baseline may 
have had on the primary efficacy endpoint (HbA1c), a post-hoc analysis was performed in a 
subgroup of patients in the FAS that excluded patients with >1% (11 mmol/mol) change in 
HbA1c from screening to baseline. All statistical analyses were performed using the SAS® 
statistical analysis software (SAS Institute, Cary, NC, USA, version 9.3) and a P value less than 
0.05 was considered statistically significant. 
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3. Results 
3.1 Patient disposition and baseline characteristics 
Patient flow through the study is presented in Figure 1. Of 268 patients who provided 
informed consent, 165 patients were randomized to 24 weeks of double-blind treatment 
(Period I: Week 0-12; Period II: Week 12-24). Six patients discontinued the study prior to the 
end of Period I; reasons for premature discontinuation are shown in Figure 1. The remaining 
159 patients entered Period II of the study. No patients were excluded from uptitration due 
to safety reasons. The FAS consisted of 164 patients in Period I, and 159 patients in Period II. 
The SAF in Periods I and II consisted of 165 and 159 patients, respectively. 
Patient demographics and baseline characteristics are presented in Table 1. Patients in both 
the placebo group and ipragliflozin group were predominantly white, aged <65 years, and 
overweight or obese. Baseline characteristics including duration of diabetes and glycemic 
parameters (HbA1c and FPG) were generally comparable between both groups (Table 1). 
The percentage of overweight/obese patients at baseline tended to be higher in the 
ipragliflozin/ipragliflozin 100 mg group than ipragliflozin/ipragliflozin 50 mg group. Baseline 
waist circumference, HbA1c levels, and FPG levels also tended to be higher in the 
ipragliflozin/ipragliflozin 100 mg group than ipragliflozin/ipragliflozin 50 mg group (Table 1). 
The mean duration of exposure to study medication in Period I was approximately 82 days 
and mean compliance rate was approximately 100% in both groups. The mean durations of 
exposure to study medication (both blinded and open-label treatment) and mean 
compliance rates in Period II were similar to those in Period I.  
3.2 Period I: Week 0–12  
Glycemic Outcomes 
Figure 2 shows the changes in glycemic variables during Period I. The mean±SD HbA1c levels 
at baseline were 8.4±0.9% (68±10 mmol/mol) and 8.5±1.0% (69±11 mmol/mol) in the 
ipragliflozin and placebo groups, respectively. After 12 weeks of treatment, significantly 
larger reductions in HbA1c were observed with ipragliflozin compared with placebo (Figure 
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2A). The mean±SD changes in HbA1c from baseline to the end of Period I were -1.0±0.9% (-
11±10 mmol/mol) in the ipragliflozin group and -0.8±1.1% (-9±12 mmol/mol) in the placebo 
group, with an adjusted mean difference of -0.3% (-3 mmol/mol) (95% CI: -0.5 to 0.0% [-6 to 
0 mmol/mol); P=0.048). Notably, a greater adjusted difference was observed in the post-hoc 
analysis that included a subgroup of patients who had stable HbA1c at baseline (n=147; 
adjusted mean difference: -0.4% (-4 mmol/mol); 95% CI: -0.6 to -0.1% (-7 to -1 mmol/mol); 
P=0.007) (Supplementary figure). At the end of Period I, a larger proportion of patients 
achieved HbA1c <7.0% (53 mmol/mol) with ipragliflozin treatment (34.9%; 95% CI: 26.0 to 
44.6%) than with placebo (23.6%; 95% CI: 13.2 to 37.0%). 
FPG also decreased to a larger extent in the ipragliflozin group from baseline to the end of 
Period I (Figure 2B). Mean changes from baseline in FPG were -18.0±32.3 mg/dL for 
ipragliflozin and -8.0±49.7 mg/dL for placebo, with an adjusted mean difference of -12.3 
mg/dL (95% CI: -23.5 to -1.1 mg/dL; P=0.032).  
Body weight and waist circumference 
Decreases in body weight from baseline to the end of Period I were observed for patients in 
both treatment groups. This reduction was significantly greater for the ipragliflozin group 
(mean±SD change: -2.01±2.47 kg) than for the placebo group (mean±SD change: -0.62±2.14 
kg). The adjusted mean difference in the changes in body weight was -1.34 kg (95% CI: -2.06 
to -0.61 kg; P<0.001). At the end of Period I, a higher proportion of patients had a weight 
reduction ≥5% in the ipragliflozin group (17.4%; 95% CI: 10.8 to 25.9%) compared to those in 
the placebo group (5.5%; 95% CI: 1.1 to 15.1%). 
The mean change in waist circumference from baseline to the end of Period I tended to be 
larger for ipragliflozin (-1.7±3.9 cm) than for placebo (-1.1±2.5 cm); however, this difference 
was not statistically significant (-0.59 cm; 95% CI: -1.65 to 0.47 cm; P=0.272). 
Safety outcomes 
There were no clinically relevant changes in clinical laboratory variables related to lipid 
profile, hematology, hepatic function, renal function, or electrolytes from baseline to the 
end of Period I in either treatment group (data not shown). No notable changes in vital signs 
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were observed between placebo and ipragliflozin; however, there was a trend towards 
reduction in standing systolic blood pressure in the ipragliflozin group at the end of Period I 
(mean change: -1.4 mmHg; 95% CI: -3.5 to 0.7 mmHg vs. 1.1 mmHg; 95% CI: -1.5 to 3.7 
mmHg in the placebo group). No major changes in ECG results were observed. 
The TEAE profile of ipragliflozin was not markedly different from that of placebo (Table 2). 
The incidence of TEAEs leading to treatment withdrawal was low in both groups (both 1.8%). 
No drug-related serious TEAEs were observed. The incidences of TEAEs of special interest 
were generally comparable between treatment groups: hypoglycemia (ipragliflozin: 11.8% 
[13/110]; placebo: 10.9% [6/55]), symptomatic urinary tract infection (ipragliflozin: 0.0% 
[0/110]; placebo: 1.8% [1/55]), and genital infection (ipragliflozin: 0.9% [1/110]; placebo: 0.0% 
[0/55]). All of the hypoglycemic events observed were mild and most were asymptomatic 
(ipragliflozin: 8.2% [9/110]; placebo: 7.3% [4/55]). 
3.3 Period II: Week 12–24 
At week 12, 38 patients on placebo and 69 patients on ipragliflozin were uptitrated by the 
addition of open-label ipragliflozin 50 mg/day to their blinded treatment (Figure 1); the 
other patients continued on their blinded treatment without uptitration in Period II. Study 
outcomes of patients in the ipragliflozin/ipragliflozin 50 mg group and the 
ipragliflozin/ipragliflozin 100 mg group are detailed below.  
Glycemic Outcomes 
At the start of Period II, patients in the ipragliflozin group who remained on 50 mg/day of 
ipragliflozin (ipragliflozin/ipragliflozin 50 mg group) had mean±SD HbA1c and FPG levels of 
6.5±0.4% (48±4 mmol/mol) and 131.1±22.4 mg/dL, respectively; both HbA1c and FPG levels 
increased slightly in this group of patients during Period II of the study, however, the 
increases were not statistically significant (Table 3). For ipragliflozin-treated patients with 
HbA1c ≥7.0% (53 mmol/mol) at the end of Period I (ipragliflozin/ipragliflozin 100 mg group), 
uptitration to 100 mg/day ipragliflozin led to an additional 13% (9/69) of patients achieving 
HbA1c <7% (53 mmol/mol) at the end of Period II; mean HbA1c and FPG levels remained 
stable in this group of patients during Period II (Table 3).  
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Body weight and waist circumference 
In ipragliflozin-treated patients who remained on 50 mg/day of ipragliflozin, mean waist 
circumference decreased significantly from Week 12 to the end of Period II (mean change 
from Week 12: -1.28 cm, 95% CI: -2.07 to -0.48 cm, P=0.002) (Table 3). There was also a 
tendency towards reduction in mean body weight; however, this was not statistically 
significant (Table 3). For patients who were uptitrated to ipragliflozin 100 mg/day, 
significant reductions were observed from Week 12 to the end of Period II for mean body 
weight (mean change from Week 12: -0.65 kg, 95% CI: -1.08 to -0.21 kg, P=0.004) and waist 
circumference (mean change from Week 12: -0.93 cm, 95% CI: -1.52 to -0.34 cm, P=0.002) 
(Table 3).  
Safety outcomes 
There were no clinically relevant changes in clinical laboratory variables related to lipid 
profile, hematology, hepatic function, renal function, and electrolytes from Week 12 to the 
end of Period II in any treatment group (data not shown). Sitting systolic blood pressure 
improved from Week 12 to the end of Period II in patients uptitrated to 100 mg ipragliflozin 
(mean change from week 12: -3.1 mmHg; 95% CI: -5.6 to -0.7 mmHg). No other notable 
changes in vital signs or ECG results were observed. 
The incidence of TEAEs and drug-related TEAEs from the start of Period II to the end of the 
study was similar between ipragliflozin-treated patients who were uptitrated to 100 mg/day 
ipragliflozin and those who remained on 50 mg/day (24.6% [17/69] vs 23.7% [9/38]) (Table 
2). No serious drug-related TEAEs were reported. One patient who was uptitrated to 100 
mg/day ipragliflozin died during the follow-up period (after end of treatment) due to acute 
myocardial insufficiency; this death was considered to be unrelated to the study medication. 
The incidence of hypoglycemia was numerically lower in ipragliflozin-treated patients who 
were uptitrated to ipragliflozin 100 mg/day than those who remained on 50 mg/day (5.8% 
[4/69] vs 10.5% [4/38]); there were no reports of symptomatic urinary tract infection or 
genital infection in either group during Period II. 
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4. Discussion 
This is the first clinical study of ipragliflozin in Russian patients with T2DM. Consistent with 
the findings of previous trials in Asian patients, addition of ipragliflozin 50 mg/day 
significantly improved glycemic control in terms of HbA1c and FPG, and resulted in body 
weight loss in Russian patients who had failed to achieve glycemic control with metformin 
alone. Uptitration of ipragliflozin from 50 mg/day to 100 mg/day in patients with a 
suboptimal response after 12 weeks led to more patients achieving glycemic control and 
further reductions in body weight and waist circumference at 24 weeks. Both 50 mg/day 
and 100 mg/day of ipragliflozin were well tolerated and no previously unreported safety 
concerns were observed. 
The HbA1c-lowering effect of ipragliflozin from baseline was similar in the present study 
compared with other ipragliflozin add-on to metformin trials conducted in Asia (-1.0% [-11 
mmol/mol] vs -0.9% [10 mmol/mol] [8, 10]). However, owing to the large response in the 
placebo group in this study, the difference between ipragliflozin and placebo was modest 
compared with previous studies (-0.3% [-3 mmol/mol] vs -1.3% [-14 mmol/mol] [8] and -0.5% 
[-6 mmol/mol] [10]). During the placebo run-in period (between screening and baseline) 
where patients received placebo while continuing metformin, we observed unexpectedly 
large changes in HbA1c in some patients, suggesting that they may not have reached a 
stable HbA1c by baseline as planned for in the study. Indeed, almost a quarter of patients in 
the placebo group did not require uptitration in Period II of the study. A post-hoc analysis 
which excluded patients with >1% (11 mmol/mol) change in HbA1c from screening to 
baseline demonstrated a greater adjusted mean difference in change in HbA1c (-0.4%) (- 4 
mmol/mol) that is more consistent with those reported in previous trials. Even so, only the 
most striking outliers were excluded in the post-hoc analysis. Further identification and 
exclusion of patients who may have had similar issues but had less extensive changes in 
HbA1c during the placebo run-in period will likely make the treatment effects of ipragliflozin 
more apparent. 
As clinical trial participation has been shown to significantly increase adherence to both 
trial-related and non trial-related treatments [20], the unexpectedly large decrease in 
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HbA1c may be associated with improved compliance with metformin and diet/exercise 
during the study. Furthermore, treatment compliance may also have been supported by 
more frequent patient contacts and regular self-monitoring of blood glucose after the start 
of the study, both of which play important roles in promoting effective diabetes 
management.  
Urinary glucose excretion caused by SGLT2 inhibition will lead to a loss of calories [21]; thus, 
it would be reasonable to expect some benefit in terms of body weight with ipragliflozin 
treatment. Studies of ipragliflozin, including ours, have consistently shown weight loss of 
approximately 2 to 3 kg after 24 weeks [8, 10]. Body composition studies have shown that 
initial weight loss is mainly due to loss of body fluids, while subsequent weight loss primarily 
results from reduced body fat [22-24]. These favorable effects on body weight and 
composition make ipragliflozin a valuable option for patients who are overweight, or for 
whom additional weight gain often caused by other antidiabetic agents (such as 
sulfonylurea, thiazolidinediones, and insulin) should be avoided [25-27]. 
The blood pressure-lowering effects of SGLT2 inhibitors have been reported in several 
studies [9, 10, 28, 29]. In this study, we also observed a reduction in systolic blood pressure 
after 12 weeks of treatment with ipragliflozin. Some have suggested that the blood 
pressure-lowering effects of SGLT2 inhibitors may be related to its osmotic diuretic effect 
and/or weight loss effect [30]. Although the exact mechanism is not yet completely 
understood, the favorable effects on blood pressure and body weight appear to be a class-
effect of SGLT2 inhibitors and may potentially offer cardiovascular benefits for patients with 
T2DM. 
In the present study, ipragliflozin was well-tolerated and showed an overall safety profile 
similar to placebo. The observed safety profile is consistent with those reported in previous 
ipragliflozin studies which included over 2000 ipragliflozin-treated patients in total [8-15, 31, 
32]. Very few patients discontinued treatment as a result of a TEAE in the present study. 
Importantly, incidences of hypoglycemia were similar between patients receiving 
ipragliflozin and those receiving placebo. This is expected as the insulin-independent mode 
of action of SGLT2 inhibitors should not lead to an increased risk of hypoglycemia, as 
  
14 
 
confirmed in a systematic review of SGLT2 inhibitors [33]. Given its mechanism, however, 
increased risks of genital infection may be expected; however the incidence of such events 
is usually relatively low as observed in our study as well as previous phase III studies of 
ipragliflozin [8, 10]. Moreover, clinical experience with SGLT2 inhibitors across 
investigational studies have shown that these events can be effectively managed without 
stopping SGLT2 inhibitor treatment as most infections are usually mild and respond to 
standard treatment [5, 34-36]. 
A key element in the design of this study that differs from previous ipragliflozin trials was 
the uptitration of patients who had not achieved an adequate level of glycemic control after 
12 weeks of treatment with the double-blind study medication. This avoids prolonged 
undertreatment of patients and mimics real-world management where patients with 
inadequately controlled T2DM can be uptitrated. A consequence of this design, however, 
was that sample sizes varied widely between treatment groups in Period II, with the 
placebo/placebo treatment group being especially small in comparison. The selection 
process for uptitration does not allow direct comparisons of outcomes between treatment 
groups in Period II as entry into these groups was not subject to randomization; however, it 
offers the opportunity to examine the effects of increasing the dose of ipragliflozin from 50 
mg/day to 100 mg/day in patients with suboptimal response. Interestingly, even though 
mean HbA1c remained unchanged following uptitration, further improvements in body 
weight and waist circumference were observed and an additional 13% of patients achieved 
HbA1c <7% (53 mmol/mol). Additionally, uptitration to 100 mg/day did not result in 
increased hypoglycemia, genital infection, or urinary tract infections. This suggests that 
increasing the dose of ipragliflozin to 100 mg/day may be clinically beneficial for a 
proportion of T2DM patients with insufficient efficacy at a dose of 50 mg/day. 
Given the study design and patient population, we believe that the study’s findings may be 
generalizable and applicable to the T2DM population in Russia. No new safety findings 
related to ipragliflozin were observed and the safety profile was comparable with the well-
established safety profile for SGLT2 inhibitors including ipragliflozin.   
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In conclusion, ipragliflozin 50 mg/day added to metformin treatment improved glycemic 
control and reduced body weight in Russian patients with T2DM who were inadequately 
controlled with metformin alone. These findings support those of earlier studies. In patients 
with inadequate glycemic control when receiving ipragliflozin 50 mg/day, uptitration to 100 
mg/day improved clinical outcomes with no additional safety concerns. Taken together, our 
results demonstrate that ipragliflozin 50 mg/day and 100 mg/day in combination with 
metformin is effective and well-tolerated in Russian patients with T2DM.    
  
16 
 
Conflicts of interest 
John Wilding has served as a consultant for Astellas, AstraZeneca, Boehringer Ingelheim, 
Janssen Pharmaceuticals, Novo Nordisk, Saonfi, Eli Lilly, and Orexigen Therapeutics. He has 
also received research support from AstraZeneca and Novo Nordisk, and served on the 
advisory panel of Astellas. Wim Wilpshaar and Reiner Tretter are employees of Astellas. All 
other authors have no relevant relationships to disclose. 
 
Acknowledgements 
Medical writing and editorial support was funded by Astellas and provided by Bao Hui Lee 
from Tech Observer Asia Pacific Pte. Ltd. 
Funding 
Astellas Pharma Europe B.V. funded and managed the study. The sponsor ensured that all 
the necessary ethic reviews and approvals were obtained, and that the clinical study was 
conducted in accordance with Good Clinical Practice. The sponsor provided investigators 
with the necessary information to conduct the study  
  
17 
 
References 
[1] International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium2017. 
[2] Dedov I, Shestakova M, Benedetti MM, Simon D, Pakhomov I, Galstyan G. Prevalence of 
type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes 
research and clinical practice. 2016;115:90-5. 
[3] Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: 
Update to a Position Statement of the American Diabetes Association and the European 
Association for the Study of Diabetes. Diabetes care. 2015;38:140-9. 
[4] Standards of Medical Care in Diabetes—2018. Diabetes care. 2018;41:S1-S159. 
[5] Dandona P, Chaudhuri A. Sodium‐glucose co‐transporter 2 inhibitors for type 2 diabetes 
mellitus: An overview for the primary care physician. International Journal of Clinical 
Practice. 2017;71:e12937. 
[6] Poole RM, Dungo RT. Ipragliflozin: First Global Approval. Drugs. 2014;74:611-7. 
[7] Inc. AP. Annual Report 2016. 2016. 
[8] Kashiwagi A, Kazuta K, Goto K, Yoshida S, Ueyama E, Utsuno A. Ipragliflozin in 
combination with metformin for the treatment of Japanese patients with type 2 diabetes: 
ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes, obesity & 
metabolism. 2015;17:304-8. 
[9] Min KW, Ku BJ, Lee JH, Kim MS, Ahn KJ, Lee MK, et al. Addition of Ipragliflozin to 
Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis 
of a Phase 3 Trial. Diabetes & metabolism journal. 2017;41:135-45. 
[10] Lu CH, Min KW, Chuang LM, Kokubo S, Yoshida S, Cha BS. Efficacy, safety, and 
tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate 
glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, 
double-blind, multicenter trial. Journal of diabetes investigation. 2016;7:366-73. 
[11] Kashiwagi A, Akiyama N, Shiga T, Kazuta K, Utsuno A, Yoshida S, et al. Efficacy and 
safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately 
controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, 
phase III EMIT study. Diabetology International. 2015;6:125-38. 
[12] Kashiwagi A, Kazuta K, Takinami Y, Yoshida S, Utsuno A, Nagase I. Ipragliflozin improves 
glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. 
Diabetology International. 2015;6:8-18. 
[13] Kashiwagi A, Shiga T, Akiyama N, Kazuta K, Utsuno A, Yoshida S, et al. Efficacy and 
safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately 
controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the 
SPOTLIGHT study). Diabetology International. 2015;6:104-16. 
[14] Fonseca VA, Ferrannini E, Wilding JP, Wilpshaar W, Dhanjal P, Ball G, et al. Active- and 
placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of 
  
18 
 
multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. Journal of diabetes 
and its complications. 2013;27:268-73. 
[15] Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and 
safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: 
a dose-finding study. Diabetes, obesity & metabolism. 2013;15:403-9. 
[16] Ishihara H, Yamaguchi S, Nakao I, Okitsu A, Asahina S. Efficacy and safety of ipragliflozin 
as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 
multi-centre, randomized, placebo-controlled, double-blind study. Diabetes, obesity & 
metabolism. 2016;18:1207-16. 
[17] Nakamura I, Maegawa H, Tobe K, Tabuchi H, Uno S. Safety and efficacy of ipragliflozin in 
Japanese patients with type 2 diabetes in real-world clinical practice: Interim results of the 
STELLA-LONG TERM post-marketing surveillance study. Expert opinion on pharmacotherapy. 
2017. 
[18] World Medical A. World medical association declaration of helsinki: Ethical principles 
for medical research involving human subjects. JAMA. 2013;310:2191-4. 
[19] Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the 
Endocrine Society. Diabetes care. 2013;36:1384-95. 
[20] van Onzenoort HA, Menger FE, Neef C, Verberk WJ, Kroon AA, de Leeuw PW, et al. 
Participation in a clinical trial enhances adherence and persistence to treatment: a 
retrospective cohort study. Hypertension (Dallas, Tex : 1979). 2011;58:573-8. 
[21] Mosley JF, Smith L, Everton E, Fellner C. Sodium-Glucose Linked Transporter 2 (SGLT2) 
Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview. Pharmacy and 
Therapeutics. 2015;40:451-62. 
[22] Iemitsu K, Kawata T, Iizuka T, Takihata M, Takai M, Nakajima S, et al. Effectiveness of 
Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes 
Duration: Interim Report of the ASSIGN-K Study. Journal of clinical medicine research. 
2017;9:793-801. 
[23] Osonoi T, Nakamoto S, Saito M, Tamasawa A, Ishida H, Osonoi Y. Efficacy of ipragliflozin 
as monotherapy or as add-on therapy with other oral antidiabetic medications for treating 
type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis 
based on patient characteristics. Journal of diabetes investigation. 2017. 
[24] Yamamoto C, Miyoshi H, Ono K, Sugawara H, Kameda R, Ichiyama M, et al. Ipragliflozin 
effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate 
diet therapy. Endocrine journal. 2016;63:589-96. 
[25] Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ. Weight change in 
people with type 2 diabetes: secular trends and the impact of alternative 
antihyperglycaemic drugs. Diabetes, obesity & metabolism. 2012;14:424-32. 
[26] Wilding J. Thiazolidinediones, insulin resistance and obesity: Finding a balance. 
International journal of clinical practice. 2006;60:1272-80. 
  
19 
 
[27] Wilding JP. The importance of weight management in type 2 diabetes mellitus. 
International journal of clinical practice. 2014;68:682-91. 
[28] Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) 
inhibitors. Journal of the American Society of Hypertension : JASH. 2014;8:330-9. 
[29] Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin reduces 
blood pressure in patients with type 2 diabetes and hypertension. Diabetes care. 
2015;38:420-8. 
[30] Majewski C, Bakris GL. Blood pressure reduction: an added benefit of sodium-glucose 
cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes care. 2015;38:429-30. 
[31] Kashiwagi A, Takahashi H, Ishikawa H, Yoshida S, Kazuta K, Utsuno A, et al. A 
randomized, double-blind, placebo-controlled study on long-term efficacy and safety of 
ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: 
results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with 
renal impairment (LANTERN) study. Diabetes, obesity & metabolism. 2015;17:152-60. 
[32] Kashiwagi A, Yoshida S, Nakamura I, Kazuta K, Ueyama E, Takahashi H, et al. Efficacy 
and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass 
index: A subgroup analysis of five randomized clinical trials. Journal of diabetes investigation. 
2016;7:544-54. 
[33] Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. 
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and 
meta-analysis. Annals of internal medicine. 2013;159:262-74. 
[34] Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and 
balanitis in patients with diabetes treated with dapagliflozin. Journal of diabetes and its 
complications. 2013;27:479-84. 
[35] Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections 
in patients with diabetes treated with dapagliflozin. Journal of diabetes and its 
complications. 2013;27:473-8. 
[36] Kohler S, Zeller C, Iliev H, Kaspers S. Safety and Tolerability of Empagliflozin in Patients 
with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. Advances in therapy. 
2017;34:1707-26. 
  
  
20 
 
  
21 
 
Tables 
 Table 1. Patient demographics and baseline characteristics (safety analysis set) 
 Characteristic Period I treatment groups  Period II treatment groups 
Placebo 
n = 55 
Ipragliflozin 
n = 110 
  Placebo/ 
Placebo 
n = 14 
Placebo/ 
Ipragliflozin  
50 mg 
n = 38  
Ipragliflozin/ 
Ipragliflozin  
50 mg 
n = 38  
Ipragliflozin/ 
Ipragliflozin  
100 mg 
n = 69 
Sex 
       
Male 22 (40.0) 48 (43.6) 
 
8 (57.1) 13 (34.2) 23 (60.5) 25 (36.2) 
Female 33 (60.0) 62 (56.4) 
 
6 (42.9) 25 (65.8) 15 (39.5) 44 (63.8) 
Race 
       
White 55 (100.0) 108 (98.2) 
 
14 (100.0) 38 (100.0) 37 (97.4) 68 (98.6) 
Asian 0 (0.0) 2 (1.8) 
 
0 (0.0) 0 (0.0) 1 (2.6) 1 (1.4) 
Age, years 58.0 ± 9.5 58.9 ± 9.3 
 
54.4 ± 10.9 59.5 ± 8.9 58.7 ± 9.9 58.9 ± 9.1 
Age <65 years 41 (74.5) 80 (72.7) 
 
12 (85.7) 26 (68.4) 26 (68.4) 52 (75.4) 
Height, cm 167.1 ± 8.8 168.1 ± 9.6 
 
171.2 ± 12.4 165.8 ± 6.7 169.1 ± 9.7 168.0 ± 9.4 
Weight, kg 89.54 ± 15.60 92.74 ± 16.24 
 
96.26 ± 14.40 87.40 ± 15.97 92.41 ± 14.53 93.46 ± 17.30 
BMI, kg/m2 31.95 ± 4.18 32.80 ± 4.76 
     
<18.5 (underweight) 0 (0.0) 0 (0.0) 
 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
18.5–24.9 (normal) 1 (1.8) 4 (3.6) 
 
0 (0.0) 1 (2.6) 3 (7.9) 1 (1.4) 
25–29.9 (overweight) 19 (34.5) 30 (27.3) 
 
3 (21.4) 16 (42.1) 9 (23.7) 20 (29.0) 
>30 (obese) 35 (63.6) 76 (69.1) 
 
11 (78.6) 21 (55.3) 26 (68.4) 48 (69.6) 
Waist circumference, cm 107.21 ± 12.30 108.46 ± 11.98 
 
111.93 ± 10.41 106.16 ± 12.92 106.78 ± 12.93 109.50 ± 11.41 
Duration of Type 2 Diabetes 
Mellitus, months 
78.7 ± 55.9 79.8 ± 62.6 
 
69.7 ± 63.4 82.1 ± 55.5 73.3 ± 71.1 83.5 ± 58.9 
HbA1c, % 8.46 ± 0.96 8.39 ± 0.93 
 
8.12 ± 1.20 8.59 ± 0.88 7.89 ± 0.75 8.66 ± 0.92 
FPG, mg/dL 175.7 ± 43.2 170.9 ± 40.5 
 
146.9 ± 36.2 185.1 ± 41.2 151.6 ± 30.2 178.8 ± 39.8 
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Values are presented as number (%) or mean ± standard deviation. 
BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin 
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Table 2. Treatment-emergent adverse events during Period I (Week 0 to 12) and during Period II to end of study (Week 12 to 24 + 4 
Weeks Follow-up) (safety analysis set) 
Variable Period I   Period II to end of study 
Placebo 
n = 55 
Ipragliflozin 
n = 110 
  Placebo/ 
Placebo 
n = 14 
Placebo/ 
Ipragliflozin 
50 mg 
n = 38  
Ipragliflozin/ 
Ipragliflozin 
50 mg 
n = 38  
Ipragliflozin/ 
Ipragliflozin 
100 mg 
n = 69 
TEAEs 19 (34.5) 32 (29.1)   5 (35.7) 14 (36.8) 9 (23.7)  17 (24.6) 
TEAEs by severitya        
Mild 13 (23.6) 26 (23.6)  4 (28.6) 9 (23.7) 8 (21.1) 13 (18.8)  
Moderate 6 (10.9) 6 (5.5)  1 (7.1) 5 (13.2) 1 (2.6) 3 (4.3) 
Severe 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 
Serious TEAEs 0 (0.0) 2 (1.8)   1 (7.1)  1 (2.6) 1 (2.6)  3 (4.3) 
TEAEs leading to withdrawal of treatment 1 (1.8) 2 (1.8)  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
TEAEs leading to death 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 
Drug-related TEAEs 4 (7.3)  12 (10.9)   2 (14.3) 2 (5.3) 1 (2.6) 6 (8.7) 
Drug-related TEAEs by severitya        
Mild 4 (7.3) 11 (10.0)  2 (14.3) 2 (5.3) 1 (2.6) 5 (7.2) 
Moderate 0 (0.0) 1 (0.9)   0 (0.0) 0 (0.0) 0 (0.0) 1 (1.4) 
Severe 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Serious drug-related TEAEs 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Drug-related TEAEs leading to withdrawal of 
treatment 
0 (0.0) 2 (1.8)   0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Drug-related TEAEs leading to death 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
TEAEs of special interest        
Hypoglycemia 6 (10.9) 13 (11.8)  2 (14.3) 2 (5.3) 4 (10.5) 4 (5.8) 
Symptomatic urinary tract infection 1 (1.8) 0 (0.0)  0 (0.0) 2 (5.3) 0 (0.0) 0 (0.0) 
Genital infection 0 (0.0) 1 (0.9)   0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Values are presented as number (%). 
Placebo/placebo: randomized to placebo, not uptitrated; placebo/ipragliflozin 50 mg: randomized to placebo, uptitrated; 
ipragliflozin/ipragliflozin 50 mg: randomized to ipragliflozin, not uptitrated; ipragliflozin/ipragliflozin 100 mg: randomized to ipragliflozin, 
uptitrated. 
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TEAEs, treatment-emergent adverse events. 
aThe most severe TEAE was counted if the patient presented with two or more TEAEs with varying severity. 
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Table 3. Changes in efficacy variables from start to end of Period II (Week 12 to 24) (full analysis set) 
  
Placebo/ 
Placebo 
n = 14 
Placebo/ 
Ipragliflozin 50 mg 
n = 38  
Ipragliflozin/ 
Ipragliflozin 50 mg 
n = 38  
Ipragliflozin/ 
Ipragliflozin 100 mg 
n = 69 
HbA1c, % 
    
Mean at Week 12 (SD) 6.41 (0.53) 8.11 (0.85) 6.49 (0.37) 7.83 (0.68) 
Mean at Week 24 (SD) 6.31 (0.55) 7.71 (0.88) 6.66 (0.45) 7.83 (0.85) 
Mean change from Week 12 
(95% CI)* 
-0.10 -0.40 0.16 0.00 
(-0.38, 0.18) (-0.57, -0.23) (-0.01, 0.33) (-0.13, 0.12) 
P value* 0.475 <0.001 0.06 0.982 
FPG, mg/dL 
    Mean at Week 12 (SD) 121.6 (24.0) 181.3 (45.1) 131.1 (22.4) 163.2 (35.0) 
Mean at Week 24 (SD) 129.2 (17.9) 163.6 (32.1) 133.9 (21.0) 161.2 (36.9) 
Mean change from Week 12 
(95% CI)* 
7.6 -17.7 2.8 -2.0 
(-8.6, 23.9) (-27.6, -7.8) (-7.0, 12.7) (-9.3, 5.3) 
P value* 0.355 <0.001 0.57 0.588 
Body weight, kg     
Mean at Week 12 (SD) 94.96 (13.79) 87.06 (15.25) 89.87 (14.22) 91.72 (17.68) 
Mean at Week 24 (SD) 94.32 (13.89)  86.00 (15.03) 89.38 (14.85) 91.08 (18.01) 
Mean change from Week 12 
(95% CI)* 
-0.64 -1.06 -0.48 -0.65 
(-1.60, 0.33) (-1.65, -0.48) (-1.07, 0.10) (-1.08, -0.21) 
P value* 0.195 <0.001 0.107 0.004 
Waist circumference, cm     
Mean at Week 12 (SD) 109.6 (9.9) 105.5 (13.5) 104.2 (12.2) 108.2 (12.1) 
Mean at Week 24 (SD) 109.1 (10.6) 104.8 (13.2) 102.9 (12.0) 107.2 (12.2) 
Mean change from Week 12 
(95% CI)* 
-0.50 -0.72 -1.28 -0.93 
(-1.81, 0.81) (-1.52, 0.08) (-2.07, -0.48) (-1.52, -0.34) 
P value* 0.453 0.076 0.002 0.002 
*ANOVA model with treatment as fixed effect.  
Placebo/placebo: randomized to placebo, not uptitrated; placebo/ipragliflozin 50 mg: randomized to placebo, uptitrated; 
ipragliflozin/ipragliflozin 50 mg: randomized to ipragliflozin, not uptitrated; ipragliflozin/ipragliflozin 100 mg: randomized to 
ipragliflozin, uptitrated. 
FPG, fasting plasma glucose; HbA1c, glycated hemoglobin 
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Figures 
 
Figure 1. Patient flow through the study. Patients entered a 2-week single-blind placebo 
run-in period. Eligible patients were randomized to receive double-blind randomized study 
medication (placebo or ipragliflozin 50 mg/day) for 24 weeks. At the end of Period I (Week 
0-12), patients with HbA1c ≥7.0% and who did not have intolerable adverse events 
potentially related to ipragliflozin were uptitrated by addition of open-label ipragliflozin 50 
mg/day to their blinded treatment for a further 12 weeks (Period II: Week 12-24). All 
patients were followed for a further 4 weeks after the end of treatment. Placebo/placebo: 
randomized to placebo, not uptitrated; placebo/ipragliflozin 50 mg: randomized to placebo, 
uptitrated; ipragliflozin/ipragliflozin 50 mg: randomized to ipragliflozin, not uptitrated; 
ipragliflozin/ipragliflozin 100 mg: randomized to ipragliflozin, uptitrated. 
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Figure 2. Time-courses of (A) glycated hemoglobin (HbA1c) and (B) fasting plasma glucose 
(FPG) measurements during Period I. Values are mean ± standard deviation. CI, confidence 
interval. *ANCOVA model including treatment as fixed effect, center as random effect and 
corresponding baseline value as a covariate.  
